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Abstract
Purpose of review—The protein tyrosine phosphatase Shp2 is encoded by PTPN11 and 
positively regulates physiologic hematopoiesis. Mutations of PTPN11 cause the congenital 
disorder Noonan syndrome and pathologically promote human leukemias. Given the high 
frequency of PTPN11 mutations in human disease, several animal models have been generated to 
investigate Shp2 in hematopoietic stem cell (HSC) function and leukemic transformation.
Recent findings—Two independent animal models bearing knockout of Shp2 in hematopoietic 
tissues clearly demonstrate the necessity of Shp2 in HSC repopulating capacity. Reduced HSC 
quiescence and increased apoptosis accounts for diminished HSC function in the absence of Shp2. 
The germline mutation Shp2D61G enhances HSC activity and induces myeloproliferative disease 
(MPD) in vivo by HSC transformation. The somatic mutation Shp2D61Y produces MPD in vivo 
but fails to induce acute leukemia, whereas somatic Shp2E76K produces MPD in vivo that 
transforms into full-blown leukemia. HSCs expressing Shp2D61Y do not generate MPD in 
recipient animals upon transplantation, whereas Shp2E76K-expressing HSCs yield MPD as well 
as acute leukemia in recipient animals. The mechanisms underlying the unique functions of 
Shp2D61Y and Shp2E76K in HSC transformation and leukemogenesis continue to be under 
investigation.
Summary—Further understanding of the physiologic and pathologic role of Shp2 in 
hematopoiesis and leukemogenesis, respectively, will yield information needed to develop 
therapeutic strategies targeted to Shp2 in human disease.
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PROTEIN TYROSINE PHOSPHATASE, Shp2
The protein tyrosine phosphatase Shp2 was originally cloned 20 years ago [1,2], and has 
been extensively studied by multiple investigators at the biochemical, physiological, and 
pathological levels [3,4,5]. Shp2 was immediately identified as an intriguing signaling 
molecule due to its two Src homology 2 domains at its aminoterminal end. Shp2 also 
contains a phosphatase domain, a proline-rich motif, and carboxyl-terminal phosphotyrosyl 
residues that also contribute to its signaling capacities [4]. Shp2 participates in myriad 
signaling cascades including the Ras-mitogen-activated protein kinase, the JAK–STAT, and 
phosphoinositol 3-kinase–AKT pathways, and positively contributes to multiple cellular 
functions including proliferation, differentiation, cell cycle maintenance, and migration 
[3,4,6,7]. Although a protein tyrosine phosphatase, which is traditionally thought to 
inactivate kinases and to serve as a negative regulator of cell function, Shp2 has been shown 
to promote cell growth and function by both upregulating positive signaling pathways [4,7] 
and by downregulating negative signaling pathways [6]. Shp2 function depends on its 
phosphatase as well as it adapter function. Although the physiologic substrate of Shp2 
remains uncertain, it is clear that its phosphatase function is necessary to support its full role 
in response to multiple growth factors and cytokines. On the other hand, loss of phosphatase 
activity does not void the positive signaling function of Shp2, which has been demonstrated 
most dramatically in individuals with the congenital disorder LEOPARD syndrome 
(multiple lentigenes, electrocardiographic conduction abnormalities, ocular hypertelorism, 
pulmonic stenosis, abnormal genitalia, retardation of growth, sensorineural deafness), who 
bear PTPN11 mutants lacking phosphatase function [8,9], but are phenotypically similar to 
individuals with Noonan syndrome, who bear PTPN11 mutants with elevated phosphatase 
function [10]. The present review highlights the several animal models used to delineate the 
functional role of wild-type Shp2 as well as Shp2 gain-of-function mutants in 
hematopoiesis, hematopoietic stem cell (HSC) biology, myeloproliferative disorder, and 
acute leukemia.
Shp2 IN NORMAL HEMATOPOIESIS AND HEMATOPOIETIC STEM CELL 
FUNCTION
Although Shp2 is ubiquitously expressed, its role in hematopoiesis became clear early on 
and has been studied in greater depth and detail than in any other tissue. Initial studies using 
murine embryonic stem cells bearing an exon 3 deletion from PTPN11 resulting in a 
truncated protein lacking amino acids 46–110 demonstrated impaired embryonic stem cell-
derived erythroid and myeloid progenitor development and reduced contribution to 
hematopoietic tissues in chimeric mice [11,12]. Further studies demonstrated that Shp2 is 
necessary in the initial steps of embryonic stem cell differentiation [13] and that HSCs from 
Shp2 heterozygous animals have reduced repopulating units and reduced self-renewal 
compared with wild-type animals [14]. Collectively these data suggest that Shp2 is 
important in normal hematopoiesis by promoting differentiation from very early stages of 
embryonic stem cell development and by supporting HSC function and self-renewal.
Given that animals bearing a germline knockout of Shp2 are embryonic lethal [15], two 
independent animal models bearing a conditional targeted PTPN11 allele have been 
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developed in the labs of Dr Benjamin Neel [16] and Dr Gen-Sheng Feng [17] and crossed 
with Mx1-Cre-positive transgenic animals, in order to knockout Shp2 expression in 
hematopoietic tissues upon treatment with polyI : polyC. Both animal models lacking Shp2 
expression demonstrated cytopenia in peripheral blood and bone marrow [18■■,19■■]. 
Upon phenotypic analysis of various hematopoietic cell lineages, absolute numbers of Lin-
negative Sca1-positive Kit-positive (LSK) cells, common lymphoid progenitors, common 
myeloid progenitors (CMP), granulocyte– monocyte progenitors (GMPs), and 
megakaryocyte–erythroid progenitors (MEPs) were all markedly reduced in both polyI : 
polyC-treated animal models (Fig. 1a).
To examine HSC function in the absence of Shp2, Zhu et al. [19■■] transplanted bone 
marrow cells from polyI : polyC-treated Shp2flox/flox :Mx1-Cre-negative or Shp2flox/flox : 
Mx1-Cre-positive animals into lethally irradiated recipients with wild-type competitor bone 
marrow cells at a ratio of 1:1 and 4:1. Shp2-deficient HSCs failed to reconstitute lethally 
irradiated recipients, and Shp2 null cells gave rise to few, if any, blood cells in the 1: 1 ratio. 
Consistent with the findings using the Shp2 heterozygous mouse model described above 
[14], these data suggest that Shp2 is important for HSC function in vivo. As bone marrow 
cells from polyI : polyC-treated Shp2flox/flox :Mx1-Cre-positive donor mice failed to 
reconstitute lethally irradiated wildtype recipients, experiments were performed to test the 
importance of Shp2 on HSC maintenance and expansion following engraftment by treating 
recipient animals with polyI : polyC after transplantation [19■■]. Bone marrow cells from 
untreated Shp2flox/flox : Mx1-Cre-negative or Shp2flox/flox : Mx1-Cre-positive mice were 
first transplanted into lethally irradiated wild-type recipient animals followed by treatment 
with polyI : polyC 4 weeks posttransplant. Animals transplanted with Shp2flox/flox : Mx1-
Cre-negative cells demonstrated similar levels of chimerism regardless of whether the donor 
mice were treated with polyI : polyC prior to transplantation or whether the recipient mice 
were treated with polyI : polyC after transplantation. In contrast, whereas recipient animals 
transplanted with Shp2flox/flox :Mx1-Cre-positive cells from poly-I:polyC-treated donors 
demonstrated very low levels of hematopoietic reconstitution derived from the Shp2flox/flox : 
Mx1-Cre-positive cells, recipient animals transplanted with Shp2flox/flox : Mx1-Cre-positive 
cells and treated with polyI : polyC posttransplantation demonstrated significantly higher 
levels of Shp2flox/flox : Mx1-Cre-positive cell-derived hematopoiesis, although not as high as 
that achieved with Shp2flox/flox : Mx1-Cre-negative cells [19■■]. Chan et al. [18■■] 
performed similar studies by transplanting bone marrow cells from Mx1-Cre-positive; 
PTPN11flox/flox, Mx1-Cre-positive; PTPN11flox/+, and Mx1-Cre-positive; PTPN11+/+ 
animals into lethally irradiated recipients and treating recipients with polyI : polyC 5 weeks 
posttransplantation. Although they observed a reduction of donor chimerism from cells 
bearing a homozygous deletion of Shp2 similar to that of Zhu et al. [19■■], they also found 
that transplantation of cells bearing a heterozygous deletion of Shp2 (Mx1-Cre-positive; 
PTPN11flox/+) yielded chimerism intermediate between the wild-type and the homozygous 
cells, indicating that Shp2 function in HSCs acts in a gene dosage-dependent manner 
[18■■] (Fig. 1a).
The finding that transplantation of Shp2 homozygous cells from both untreated animal 
models initially generated chimerism levels similar to that of transplanted wild-type (i.e., 
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Mx1-Cre-negative) cells, with a precipitous drop in chimerism only after polyI : polyC 
treatment, suggested that HSC homing and initial engraftment depends on Shp2. In order to 
examine the effects of loss of Shp2 on homing, Zhu et al. [19■■] transplanted CFDA-SE-
labeled Shp2-deleted or control Lin-negative bone marrow cells into lethally irradiated wild-
type mice, and recipients were sacrificed after 16h to quantify CFDA-SE levels in the bone 
marrow. Animals transplanted with Shp2-deficient cells had significantly reduced CFDA-
SE-stained cells compared with animals transplanted with control cells, indicating the need 
of Shp2 for normal HSC homing. To define a cellular mechanism that may underlie reduced 
homing and engraftment of Shp2-deficient cells, phenotypically defined HSCs were 
evaluated for cell cycle status. Studies from both the Neel laboratory [18■■] and the Feng 
laboratory [19■■] demonstrated that Shp2-deficient cells are less quiescent with reduced 
cells in G0/G1 stage of the cell cycle (Fig. 1a). Similar results were found in phenotypically 
defined Shp2 heterozygous HSCs [14]. Taken together, these data support the importance of 
Shp2 in homing and engraftment of HSCs and imply that reduced Shp2 levels may drive 
cells from cell cycle quiescence, potentially leading to HSC exhaustion, and accounts for the 
finding that animals lacking hematopoietic cell Shp2 expression are much more sensitive to 
treatment with the cell cycle-specific myeloablative treatment, 5-fluorour-acil [19■■].
To determine whether Shp2 functions in a cell autonomous manner in HSCs, or whether 
Shp2 function is needed in the microenvironment to regulate HSCs, reciprocal transplants 
were performed. Wild-type bone marrow (either unfractionated or LSK cells) transplanted 
into polyI : polyC-treated Shp2flox/flox : Mx1-Cre-positive or Shp2flox/flox : Mx1-Cre-
negative (Feng model) lethally irradiated recipients produced similar levels of hematopoietic 
reconstitution [19■■]. Consistently, wild-type bone marrow transplanted into lethally 
irradiated Mx1-Cre-positive; PTPN11flox/+ or Mx1-Cre-positive; PTPN11flox/flox animals 
(Neel model) followed by treatment with polyI : polyC also yielded similar levels of 
hematopoiesis with animals remaining healthy with normal blood counts for at least 20 
weeks postpolyI : polyC [18■■]. These combined studies nicely corroborate that Shp2 
functions in a cell autonomous manner in HSCs.
The molecular mechanism underlying how Shp2 modifies HSC and progenitor function has 
also been investigated. Zhu et al. [19■■] found that Kit expression is reduced in the bone 
marrow of Shp2flox/flox: Mx1-Cre-positive animals, and further demonstrated using 
chromatin immunoprecipitation and luciferase studies that GATA2 binding to the Kit 
promoter and Kit promoter activity, respectively, are regulated by Shp2 expression. Chan et 
al. [18■■] examined the role of p53 in the increased apoptosis levels observed in Lin-
negative Kitpositive and LSKCD150-positive cells from polyI : polyC-treated Mx1-Cre-
positive; PTPN11flox/flox animals. A dominant negative p53 failed to inhibit upregulation of 
proapoptotic Noxa expression in LSK cells lacking Shp2 expression, suggesting that loss of 
Shp2 induces p53-independent apoptosis in HSC/progenitors [18■■]. Using Shp2 
knockdown in 32Dcl3 cells, Zhang and Friedman [20] found reduced CCAT/enhancer 
binding protein α (C/EBPα) expressionat the RNA and protein levels and reduced 
granulopoietic differentiation, and further observed that knockdown of Erk reduced 
proliferation, but did not change C/EBPα protein expression or granulopoiesis, suggesting a 
unique Erk-independent role of Shp2 in granulopoiesis.
Nabinger and Chan Page 4
Curr Opin Hematol. Author manuscript; available in PMC 2015 July 07.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Shp2 IN HUMAN HEMATOPOIESIS
Most studies have utilized murine models to study Shp2 function in hematopoiesis; 
therefore, Li et al. [21■■] used a lentiviral system to infect human CD34+ cells with 
shRNA targeted to Shp2 in order to better understand the role of Shp2 in human 
hematopoiesis. Consistent with findings using murine cells, human CD34+ cells deficient in 
Shp2 have reduced growth factor-stimulated proliferation and survival and demonstrate 
reduced myeloid and erythroid cell differentiation compared with control cells [21■■]. 
Biochemically, loss of Shp2 in CD34+ cells results in reduced growth factor-activated Erk, 
AKT, and JAK/STAT signaling and reduced expression of the antiapoptotic genes MCL1 
and BCLXL [21■■]. These studies are particularly relevant and timely given the aberrant 
Shp2 expression and function in human HSC-related diseases.
Shp2 IN HUMAN DISEASE AND LEUKEMOGENESIS
Given the critical role of Shp2 in HSC function and in human hematopoiesis, it is not 
surprising that dysregulated Shp2 function is commonly found in human myeloid leukemias. 
Shp2 was originally found to be affiliated with human disorder when approximately 50% of 
individuals with the congenital disorder Noonan syndrome were found to bear germline 
gain-of-function mutations in PTPN11 [10]. Although individuals with Noonan syndrome 
demonstrate several congenital anomalies including cardiac defects, craniofacial 
abnormalities, and short stature, it was also noted that Noonan syndrome patients rarely 
develop the uncommon childhood leukemia, juvenile myelomonocytic leukemia (JMML). 
This observation led to the finding that children with sporadic JMML bear somatic gain-of-
function PTPN11 mutations in 35% of cases [22]. These gain-of-function mutations are 
typically point mutations in the N-SH2 (amino-terminal Src homology 2) domain or, less 
commonly, in the phosphatase domain, which prevent autoinhibition between the catalytic 
domain and the N-SH2 domain and render the protein constitutively active [5,10,22].
In addition to JMML, gain-of-function mutations in PTPN11 have also been rarely 
associated with other hematologic malignancies including pediatric and adult acute myeloid 
leukemia (AML) [23–25], chronic myelomonocytic leukemia [26], B-cell acute 
lymphoblastic leukemia/lymphoma (B-ALL) [27], and pediatric and adult myelodysplastic 
syndrome (MDS) [26,28,29]. The biological differences underlying the relatively low 
frequency of PTPN11 mutations in most hematologic malignancies compared with the high 
frequency found in JMML is unclear; however, one hypothesis suggests that in AML and 
MDS, PTPN11 mutations (leading to altered signal transduction pathways and increased 
proliferation) may need to work in a cooperative fashion with transcription factor mutations 
(leading to reduced cellular differentiation). Consistent with this notion, in AML and MDS, 
PTPN11 mutations are not uncommonly found to be concurrent with recurrent leukemia-
associated cytogenetic anomalies [23,30]. Consistently, the PTPN11 gain-of-function mutant 
Shp2E76K has been shown to cooperate with overexpression of HoxA10 and with 
deficiency of interferon consensus sequence-binding protein in the induction of AML 
[31,32].
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Although Shp2 mutations are uncommonly found in adult leukemias, Shp2 has been shown 
to be overexpressed at both the protein and RNA levels in several human AML cell lines 
and primary samples [33]. Upon immunoblot analyses, Xu et al. [33] detected two distinct 
Shp2 bands and, interestingly, the upper (tyrosine phosphorylated) band was preferentially 
expressed in both the membranous and nuclear fraction of leukemic cells. Additionally, 
increased Shp2 phosphorylation in primary leukemic cells correlated with hyperplastic bone 
marrow, suggesting that phospho-Shp2 levels are positively associated with high 
proliferative potential of leukemic bone marrow cells. Finally, using the Breakpoint Cluster 
Region – Abelson kinase-positive human cell line K562, which has a high expression of 
Shp2, reduction of Shp2 expression using antisense Shp2 onligonucleotides induced 
apoptosis and inhibited leukemic cell clonogenic growth [33].
The first human PTPN11 mutation modeled in animals, generated in the laboratory of Dr 
Benjamin Neel, was engineered to constitutionally express the germline Noonan syndrome 
mutation, Shp2D61G [34]. Homozygous PTPN11D61G/D61G animals were embryonic lethal; 
however, approximately 50% heterozygous PTPN11D61G/+ animals were viable. Surviving 
pups developed similar characteristics to individuals with Noonan syndrome including short 
stature, craniofacial abnormalities, cardiac defects, and indolent myeloproliferative disorder 
(MPD) [34] (Fig. 1b). Studies performed in the laboratory of Dr Cheng-Kui Qu using this 
animal model [35] demonstrated that LSK cells as well as the phenotypically defined 
progenitors CMP, GMP, and MEP in the PTPN11D61G/+ animals were increased in both the 
bone marrow and spleen and that, functionally, HSCs from the PTPN11D61G/+ animals 
demonstrated increased repopulating capacity compared with control cells [35] (Fig. 1b). 
Furthermore, transplantation of whole bone marrow or LSK cells was able to produce MPD 
in recipient animals (Fig. 1b), whereas transplantation of committed progenitors (CMP or 
GMP) failed to produce MPD [35]. In contrast, as described in detail below, animals 
conditionally expressing somatic gain-of-function Shp2 mutants (Shp2D61Y and 
Shp2E76K) in hematopoietic tissues demonstrated reduced bone marrow phenotypic HSCs 
and progenitors as well as reduced HSC function [36,37■■] (Fig. 1b, c, and d). These 
phenotypic distinctions may be due to the fact the Shp2D61G is a less severe mutation with 
lower phosphatase activity compared with Shp2D61Y and Shp2E76K [38], or may be due to 
the broader, global expression of Shp2D61G that may exert microenvironmental effects in 
the PTPN11D61G/+ animals.
To simulate human JMML, Shp2D61Y or Shp2E76K (the two most common PTPN11 
mutations found in individuals with JMML) were retrovirally transduced into 5-fluorouracil-
treated bone marrowcellsfrom Balb/c mice and transplanted into lethally irradiated 
syngeneic recipients. Approximately 50% of animals developed leukocytosis and 
splenomegaly followed by death between 6–7 months, and over 90% eventually succumbed 
to death by 12–18 months posttransplant [39]. In order to develop a more physiologic model 
of mutant Shp2-induced leukemia, a conditional knockin of PTPN11D61Y was generated 
expressing mutant Shp2 under its endogenous promoter and crossed with Mx1-Cre-positive 
transgenic animals [36]. PolyI: polyC-induced Cre expression is able to remove a stop codon 
within the PTPN11D61Y allele allowing gain-of-function Shp2D61Y to be expressed. PolyI : 
polyC-treated PTPN11D61Y/+; Mx1-Cre-positive mice had an average survival rate of 45 
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weeks and typically succumbed to MPD with marked leukocytosis and hepatosplenomegaly, 
whereas the control animals lived at least 75 weeks without any major indications of disease. 
In contrast to those found in the PTPN11D61G/+ animals [35], the bone marrow LSK cells, 
long-term HSC (LT-HSC, LSK, FLK2−, CD34−), short-term HSC (ST-HSC, LSK, FLK2−, 
CD34+), and phenotypic progenitor populations were significantly reduced in the 
PTPN11D61Y/+; Mx1-Cre-positive animals (Fig. 1c). Interestingly, however, the numbers of 
splenic LSK cells as well as ST-HSC and multipotent progenitors (MPP, LSK, FLK2+, 
CD34+) were increased in PTPN11D61Y/+; Mx1-Cre-positive animals (Fig. 1c), suggesting 
mutant Shp2 in the bone marrow encourages cells from the quiescent bone marrow 
compartment to migrate and expand into the spleen. Transplantation of either bone marrow 
or spleen cells from diseased PTPN11D61Y/+; Mx1-Cre-positive animals into lethally 
irradiated syngeneic recipients revealed that long-term engraftment of these mutant HSCs 
failed to give rise to MPD in recipient animals [36] (Fig. 1c).
A conditional knockin of PTPN11E76K was also generated, as Shp2E76K is the most 
common Shp2 mutation found in JMML [37■■]. PTPN11E76K/+ animals were crossed with 
Mx1-Cre transgenic animals and polyI : polyC-treated PTPN11E76K/+; Mx1-Cre-positive 
animals develop fully penetrant MPD. Very similar to the PTPN11D61Y/+; Mx1-Cre-positive 
animals, bone marrow LSK cells, LT-HSCs, ST-HSCs, and phenotypic progenitors were 
significantly reduced in the polyI : polyC-treated PTPN11E76K/+; Mx1-Cre-positive mice 
compared with control mice (Fig. 1c). Additionally, the PTPN11E76K/+ animals also 
demonstrate a significant increase in splenic LSK cells [37■■]. Both the Ptpn11D61Y/+; 
Mx1-Cre-positive and PTPN11E76K/+; Mx1-Cre-positive animals demonstrate reduced 
quiescence and increased cycling of phenotypic HSCs, suggesting that mutant Shp2-induced 
HSCs have accelerated differentiation, increased movement to the spleen, and expansion 
within the splenic microenvironment [36,37■■] (Fig. 1c and d). Although the conditional 
PTPN11 knockout models [18■■,19■■] and the gain-of-function PTPN11 knockin models 
(Shp2D61G, Shp2D61Y, and Shp2E76K) [34,36,37■■] all demonstrate increased HSC 
cycling (i.e., reduced HSC quiescence), the HSCs lacking Shp2 expression demonstrate 
elevated apoptosis, whereas HSCs expressing Shp2 gain-of-function mutants demonstrate 
significantly reduced apoptosis compared with control cells (Fig. 1a–d). Thus, although 
Shp2 deficiency and Shp2 gain-of-function mutants both cause reduced HSC quiescence, the 
difference in HSC apoptosis likely accounts for the dramatically different phenotypes of 
bone marrow failure and MPD development, respectively.
Distinct from the PTPN11D61Y/+; Mx1-Cre-positive animals, the PTPN11E76K/+; Mx1-Cre-
positive animals commonly progressed from MPD to acute leukemias including AML, T-
cell-ALL (T-ALL), and B-ALL [37■■] (Fig. 1d). As the PTPN11E76K/+ animals progressed 
to full blown leukemias of various types, Xu et al. [37■■] next considered at which stage in 
hematopoiesis the initial leukemia-initiating stem cells (LSCs) became amplified 
contributing to leukemia. To test this, LSK cells from PTPN11E76K/+ animals with MPD 
were transplanted into lethally irradiated recipients. Recipient animals all developed MPD, 
and 40% of them progressed to acute leukemia, suggesting that the LSCs are present within 
the stem cell/immature progenitor population. To determine whether the LSCs could also be 
derived from more mature, lineage-committed progenitors, transplants were performed using 
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cells bearing the knockin of the PTPN11E76K allele specifically in GMPs, early-stage T 
cells, and early-stage B cells using LysM-Cre, LCK-Cre, and CD19-Cre, respectively. 
Between 40 and 50% of recipient animals developed AML, T-ALL, and B-ALL in a 
lineage-specific manner, and these leukemias persisted in lineage-specific primary and 
secondary transplant recipients. These findings suggest that HSC self-renewal programs are 
not required for Shp2E76K-induced transformation to LSCs.
The apparent functional difference between Shp2D61Y, which clearly induces MPD but 
fails to induce full-blown acute leukemia, and Shp2E76K, which is able to induce full-blown 
leukemia of various lineages, may be due to the increased phosphatase activity of 
Shp2E76K, which is known to have the highest phosphatase activity of the various gain-of-
function Shp2 mutants tested [38]. However, although there is no direct comparison to 
Shp2D61Y-expressing cells, Xu et al. [37■■] also found that bone marrow and splenic 
cells from PTPN11E76K/+; Mx1-Cre-positive animals commonly demonstrated aneuploidy. 
Because aneuploidy is known to be associated with mitosis abnormalities, they next 
examined the centrosomes of mutant-expressing PTPN11E76K/+ cells and found 
amplification of and Shp2 localization to centrosomes in preleukemic PTPN11D61Y/+ mice. 
These novel findings provide at least a partial explanation for nuclear localization of Shp2 
previously observed in human leukemia samples [33]. Future studies to examine potential 
genetic instability induced by other gain-of-function Shp2 mutants as well as to further study 
the function of nuclear Shp2 will provide further insight into the mechanisms underlying 
mutant Shp2-induced leukemogenesis.
CONCLUSION
The protein tyrosine phosphatase Shp2 has been heavily studied over the past two decades 
and has been implicated in the congenital disorder Noonan syndrome as well as in JMML 
and less commonly in other hematologic malignancies. Further understanding of the 
molecular mechanisms of wild-type Shp2 and the pathogenesis of mutant Shp2 will provide 
the needed knowledge to develop and implement therapeutic strategies targeted to Shp2 in 
human disease.
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KEY POINTS
• The protein tyrosine phosphatase Shp2 plays a crucial role in physiologic 
hematopoiesis and hematopoietic stem cell function.
• Loss of Shp2 in hematopoietic stem cells (HSCs) results in reduced quiescence 
and increased apoptosis, leading to substantially reduced HSC-repopulating 
activity.
• Endogenous expression of gain-of-function mutants Shp2D61Y and Shp2E76K 
reduces HSC-repopulating activity and promotes mobilization of phenotypic 
HSCs from the bone marrow to the spleen.
• Endogenous expression of gain-of-function Shp2D61Y induces 
myeloproliferative disease, but not acute leukemia.
• Endogenous expression of gain-of-function Shp2E76K induces 
myeloproliferative disease that progresses to acute leukemia of multiple 
lineages.
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FIGURE 1. 
Schematic diagram comparing the hematopoietic progenitor, hematopoietic stem cell, and 
leukemia transformation phenotypes of murine models bearing knockout of Shp2 (a), 
germline knockin of Shp2D61G (b), somatic knockin of Shp2D61Y (c), or somatic knockin 
of Shp2E76K (d). BM, bone marrow; HSC, hematopoietic stem cell; LSK, Lin-negative 
Sca1-positive Kit-positive; MPD; myeloproliferative disorder; PB, peripheral blood; WBC, 
white blood cell.
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